Clinical trials: Virus Shedding
HIV
Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir
The purpose of this trial is to learn about potential interactions between raltegravir and a birth control pill in HIV+ women. The investigators plan to enroll HIV+ women who are on steady state raltegravir containing highly…
- Trial name
- NCT01597180
- Where
- United States
- Sponsor
- University of North Carolina, Chapel Hill
Influenza
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain
This randomized, double-blind, multi-center study of Tamiflu (Oseltamivir) will evaluate the efficacy against viral activity, the effectiveness in resolving the disease symptoms, and the safety and tolerability in patients with…
- Trial name
- NCT01032837
- Testing
- Oseltamivir
- Where
- 100 sites in United States
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
Covid19, Asymptomatic Shedding Viral
COVID-19 Rapid Testing for Self-Administration Among an Asymptomatic Sample
Point-of-care testing can provide an additional layer of protection to reduce transmission of COVID-19 safely and effectively in the population, and if such tests can be self-administered, barriers to access may be reduced.
- Trial name
- NCT04896710
- Testing
- SD Biosensor
- Where
- Canada
- Volunteers
- 569 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Poliomyelitis
Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults
This first-in-human (FIH) phase 1 study is designed to evaluate in contained conditions the safety, immunogenicity, shedding, and genetic stability of two novel oral polio vaccine type 2 (nOPV2) vaccine candidates in IPV-primed…
- Trial name
- nOPV2M4a (NCT03430349)
- Testing
- Novel OPV2 candidate 1, Novel OPV2 candidate 2
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pierre Van Damme
Genital Herpes
HSV-2 Shedding Resolution After Acyclovir Treatment
The purpose of the study is to evaluate the pattern of viral shedding after beginning treatment with acyclovir for a clinical recurrence of genital herpes and to compare it with the pattern of viral shedding during an untreated…
- Trial name
- NCT00495573
- Testing
- acyclovir
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Washington
Ulcer, Herpes Genitalis
Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212)
Herpes virus type 2 (HSV-2) infection - as a cofactor of human immunodeficiency virus (HIV) transmission - can be targeted by anti-herpetic specific drugs, either as a continuous prophylactic treatment during its asymptomatic…
- Trial name
- NCT00158483
- Testing
- Acyclovir (ACV)
- Where
- 3 sites in Central African Republic, Ghana
- Volunteers
- 449 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Covid19, SARS-CoV Infection
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
Administration of Zinc and resveratrol or double placebo for a period of 5 days and will be monitored for a 14 day period in covid-19 positive patients in an outpatient setting
- Trial name
- Reszinate (NCT04542993)
- Testing
- Zinc Picolinate, Resveratrol
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Swedish Medical Center
Infections, Herpesviridae
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.
- Trial name
- NCT00116844
- Testing
- Valaciclovir
- Where
- 17 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections, Herpesvirus 2, Human
Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2)
The purpose of this study is to determine whether acyclovir is effective in suppressing HIV viral load in women infected with both HIV-1 and herpes simplex virus type 2 (HSV-2) who are starting HIV treatment for the first time.
- Trial name
- NCT00371592
- Testing
- Acyclovir
- Where
- Peru
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam…
- Trial name
- NCT07332000
- Testing
- aglatimagene besadenovec + valacyclovir, External Beam Radiation Therapy (EBRT)
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Candel Therapeutics, Inc.
SARS-CoV-2 Infection, Covid19
COVID-19: Infectious Potential of SARS-CoV-2 Intestinal Shedding in Pediatric Patients (INPOSIS)
The clinical courses of COVID-19 in children are reportedly mild, and may therefore readily escape diagnosis. Prolonged intestinal virus shedding has been reported in children, thus rendering the pediatric population a…
- Conditions
- SARS-CoV-2 Infection, Covid19, Intestinal Infection
- Trial name
- INPOSIS (NCT05055466)
- Where
- 4 sites in Austria
- Volunteers
- 283 people
- Sponsor
- St. Anna Kinderkrebsforschung
HIV, HIV Infections
Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding
The purpose of the study is to determine how common herpes is among persons with HIV who do not know they have it and if valacyclovir reduces outbreaks of herpes, the amount of HIV in the blood, and the amount of HSV in bodily…
- Trial name
- NCT00803543
- Testing
- Valacyclovir
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Respiratory Tract Viral Infection
Assessement of Viral Shedding Duration After a Respiratory Tract Infection in Oncology and Hematology Patients
The purpose of this study is to assess the duration of the viral shedding in hematology and oncology patients after a respiratory tract viral infection.
- Trial name
- ONCOVIR (NCT03389997)
- Testing
- nasal swabs
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Poitiers University Hospital
Influenza Vaccines
Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children
LAIV shedding studies in children could be an important way to confirm whether impediments to viral replication do indeed explain these observed reductions in vaccine effectiveness (VE), whether prior vaccination has any…
- Trial name
- FluSHED-2 (NCT03735147)
- Testing
- Live attenuated influenza vaccine (LAIV)
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Genital Herpes
Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
The purpose of the research study is to evaluate the effectiveness of high-dose acyclovir compared to valacyclovir for reduction of asymptomatic genital shedding in persons with genital herpes.
- Trial name
- NCT00362297
- Testing
- acyclovir, valacyclovir
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Washington
Healthy
Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects
The objectives of the study are to demonstrate the effectiveness, safety and tolerability of multiple daily doses of inhaled PUR003, in comparison with placebo, in healthy adults experimentally inoculated with Influenza…
- Trial name
- NCT00947687
- Testing
- PUR003
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pulmatrix Inc.
COVID-19
Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19
Ivermectin which is an FDA-approved broad spectrum anti-parasitic agent, has also anti-viral activity. In vitro study have shown its activity against SARS-CoV-2, however its clinical effect on patients with COVID-19 never been…
- Trial name
- NCT04429711
- Testing
- Ivermectin Oral Product
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Healthy
A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children
Open label, single arm, multicenter study of the shedding and safety of a single dose of trivalent, influenza virus vaccine live, intranasal in children 6 to < 60 months of age, with 28-day shedding follow-up and 180-day safety…
- Trial name
- NCT00344305
- Testing
- Trivalent influenza virus vaccine live, intranasal
- Where
- 16 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Genital Herpes
A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital…
- Trial name
- NCT00129818
- Testing
- Famciclovir
- Where
- 7 sites in United States
- Sponsor
- Novartis
Human Immunodeficiency Virus (HIV)
Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults
The goal of this study is to determine if there is a difference in shedding (primary objective) and in immunogenicity and safety (secondary objectives) between HIV-positive and HIV-negative children and young adults who are…
- Trial name
- QLAIV (NCT02474901)
- Testing
- Quadrivalent Live Attenuated Influenza Vaccine
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver